Compression stockings are advised to reduce the risk of travel related VTE in flights longer than 3 to 4 hours; however, the routine use of antiplatelet/anticoagulant agents is controversial. There are no studies regarding travel-related VTE risk in individuals following superficial venous intervention.
Objectives: Traditional end points, such as amputation-free survival, used to assess the clinical effectiveness of lower-limb revascularization have shortcomings because they do not account independently for wound nonhealing and recurrence or patient survival. We introduced the wound-free period (WFP), the period during which limbs maintained an ulcer-free state, and the wound-existence period (WEP) as parameters and tested their effectiveness in evaluating clinical outcomes of limbs treated using endovascular therapy (EVT) and surgical revascularization.
Methods: The medical records of patients developing lower critical limb ischemia (CLI) with tissue loss who underwent surgical or endovascular revascularization of the infrainguinal vessels were retrospectively reviewed. The risk factors for achieving wound healing and wound healing time (WHT) were analyzed using Kaplan-Meier survival curves and the Cox regression model. According to the obtained significant confounding factors, matched-pair analysis comparing EVT-first and surgical revascularization (SUR)-first treatment groups were conducted. Wound healing, WHT, WFP, and WEP were compared between the groups.
Results: In total, 304 patients underwent 364 limb revascularizations, and 194 endovascular and 170 surgical procedures were performed as first treatments. The proportion of healed wounds 1, 2, and 3 years after primary revascularization was 56.3%, 63.4%, and 64.0%, respectively. Significant risk factors for wound healing were EVT-first strategy (RR, 2.13), dialysis dependence (RR, 1.70), congestive heart failure (RR, 2.02), nonambulatory status (RR, 1.74), and Wound, Ischemia, and foot Infection (WIfI) grade (RR, 2.19). The mean WHT was 158.2 days. Significant risk factors for prolonged WHT were EVT-first strategy (RR, 1.98) and WIfI grade (RR, 1.45). The mean WFP was 713.0 days. EVT-first strategy, history of coronary artery disease, dialysis dependence, and nonambulatory status were associated with significantly shorter WFPs. The matched-pair analysis showed that compared with limbs in the EVTfirst group, those in the SUR-first group showed significantly superior wound healing (60.5% vs 73.6%), WFP (407 vs 563 days), and WEP (226 vs 119 days). In the subgroup of limbs that achieved wound healing, WEPs and WHTs were significantly longer in the EVT-first group (252 and 217 days, respectively) than in the SUR group (116 and 110 days, respectively), whereas absence of CLI recurrence and WFP were not significantly different.
Conclusions: The revascularization method (EVT or SUR first) and WIfI grade were associated with delayed wound healing and prolonged wound healing rate. The WFP and WEP parameters are useful criteria for evaluating positive limb outcomes in CLI patients. Compared with initial EVT, the SUR-first strategy seems to produce superior results in wound-healing rate, WHT, and WFP.
Author Disclosures: M. Ishida: Nothing to disclose; J. Okazaki: Nothing to disclose; K. Tanaka: Nothing to disclose. Objectives: Wound sterilization with multiple sessions of antibiotic bead placement has been described as a method to avoid graft removal in patients presenting with deep wound infection after extremity bypass. The long-term benefits of this approach remain poorly understood. We sought to determine whether graft preservation and wound sterilization with antibiotic beads affect amputation rates and patient survival.
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Long-Term Outcomes of Lower Extremity Graft
Methods: Patients who underwent operations for aortoiliac or infrainguinal aneurysmal or occlusive arterial disease were retrospectively analyzed. Those who developed deep wound infection within 90 days from the index reconstruction (infection group), had underlying exposed bypass graft, and no evidence of anastomotic or arterial bleeding, were managed with graft preservation and antibiotic bead placement every 3 to 5 days, until wound cultures became negative. This group was compared to a contemporary group of controls who underwent similar interventions but did not develop wound infection postoperatively. Primary outcome was amputation-free survival, defined as survival without major amputation. Secondary outcomes included major amputations and occurrence of anastomotic pseudoaneurysm necessitating repair. Inverse propensity score weighting was used for risk adjustment between the groups.
Results: Over an 8-year period we treated 891 patients (infection: 70, controls: 821). Patients in the infection group had higher body mass index (mean 28.5 vs 26 kg/m 2 ; P < .001) and were more likely to have prosthetic graft and axillofemoral bypass compared to controls. Amputation-free survival for the infection vs the control group was 78% vs 74% at 2 years, 62% vs 64% at 4 years, and 52% vs 54% at 6 years postoperatively (logrank test: P ¼ .88; Fig 1) . Freedom from major amputation for the infection vs the control group was 82.5% vs 83.5% at 2 years, 80.5% vs 78% at 4 years, and 80.5% vs 72% at 6 years postoperatively (log-rank test: P ¼ .59; Fig 2) . In the propensity score adjusted model, the presence of infection did not affect amputation-free survival (hazard ratio, 1.13; P ¼ .6) or major amputation (hazard ratio, 0.89; P ¼ .75). Anastomotic pseudoaneurysms occurred in 0.4% and 5.7% of controls and infected patients, respectively (P ¼ .001), and were treated with interposition graft without complications.
Conclusions: Wound sterilization with serial antibiotic bead exchange and bypass preservation is associated with excellent limb salvage and survival rates, similar to those for noninfected wounds. Close follow-up for timely detection of anastomotic pseudoaneurysm is recommended.
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Methods: This was a double-blinded, placebo-controlled trial designed to assess the safety and efficacy of intramuscular injection of autologous 
